A small number of patients in the Secondary Progressive and Chronic stages of Multiple Sclerosis (MS) have benefited (PDF) from being treated with SF1019.

SF-1019 is the platform technology of Argyll Biotechnologies. It was developed from extensive research into Biological Response Modifiers (BRMs) undertaken at: Mississippi State University; St George's, University of London (formerly St George's Hospital Medical School); Ohio University; and Methodist Hospital. Argyll Biotechnologies has transferred to Immunosyn Corporation the world-wide rights to market and distribute SF-1019.